- Home
- GSL vs AVDL Comparison
GSL vs AVDL Comparison
Compare GSL & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- AVDL
- Stock Information
- Founded
- GSL 2007
- AVDL 2015
- Country
- GSL Greece
- AVDL Ireland
- Employees
- GSL N/A
- AVDL N/A
- Industry
- GSL Marine Transportation
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- AVDL Health Care
- Exchange
- GSL Nasdaq
- AVDL Nasdaq
- Market Cap
- GSL 766.6M
- AVDL 867.3M
- IPO Year
- GSL 2006
- AVDL 1996
- Fundamental
- Price
- GSL $22.68
- AVDL $8.41
- Analyst Decision
- GSL Strong Buy
- AVDL Strong Buy
- Analyst Count
- GSL 1
- AVDL 7
- Target Price
- GSL $29.00
- AVDL $18.86
- AVG Volume (30 Days)
- GSL 320.3K
- AVDL 1.3M
- Earning Date
- GSL 03-03-2025
- AVDL 03-03-2025
- Dividend Yield
- GSL 7.94%
- AVDL N/A
- EPS Growth
- GSL 7.30
- AVDL N/A
- EPS
- GSL 8.96
- AVDL N/A
- Revenue
- GSL $701,476,000.00
- AVDL $138,160,000.00
- Revenue This Year
- GSL $6.45
- AVDL $515.49
- Revenue Next Year
- GSL N/A
- AVDL $48.85
- P/E Ratio
- GSL $2.53
- AVDL N/A
- Revenue Growth
- GSL 8.60
- AVDL 1523.50
- 52 Week Low
- GSL $18.75
- AVDL $7.39
- 52 Week High
- GSL $30.32
- AVDL $19.09
- Technical
- Relative Strength Index (RSI)
- GSL 59.05
- AVDL 45.85
- Support Level
- GSL $21.46
- AVDL $8.27
- Resistance Level
- GSL $23.30
- AVDL $9.34
- Average True Range (ATR)
- GSL 0.49
- AVDL 0.44
- MACD
- GSL 0.14
- AVDL 0.09
- Stochastic Oscillator
- GSL 74.80
- AVDL 43.29
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.